Sanofi-Aventis, a drug maker of France has launched a new age weight loss medication which works on the principle of an appetite suppressant, which means that it reduces your normal appetite sourcing weight loss.
On 6th February, 2007, Sanofi Aventis Acomplia was reported to attain French approval for sale. In France, usage of Acomplia is endorsed only for those obese patients who have type 2 diabetes, which can’t be treated with customary diabetic drugs. The France’s Transparency Committee recommended that the government would reimburse Acomplia for some obese patients with type you2 diabetes. This implies that only obese (with a BMI 30 or greater) patients who have type 2 diabetes are only eligible for a reimbursed prescription.
Acomplia constitutes Rimonabant as its main ingredient is an effective appetite suppressant. Acomplia (Rimonabant) drug is suggested to combined with a low calorie diet and regular workout regime to achieve effective weight loss.
It is already made available in the UK, Germany, Argentina, Ireland, Sweden, Holland, and Austria amid others. Some of the prospective countries to witness the availability of Acomplia (Rimonabant) include Spain, Italy, and Mexico.
Prior to beginning with this weight loss treatment it is recommended to consult a doctor, as it is an oral prescription medication. Inform your doctor about your previous and present medical record so as judge the suitability of Acomplia usage for you.
|
